G lioblastoma is a highly malignant and rapidly progressing disease. At the time of diagnosis, patients with glioblastoma frequently suffer from neurocognitive deficits.
Neurocognitive function (NCF) has been shown to be a predictor of survival in patients with recurrent malignant glioma 1 and has a direct bearing on health-related quality of life (QoL). Diminished NCF in patients with brain tumors has been associated with reduced independence, difficulty maintaining roles in the home and work environments, decreased ability to participate in daily living activities, 2 -4 and increased caregiver burden and distress. 4, 5 Neurocognitive decline often precedes reductions in daily functioning and QoL in these patients 1,6 -8 and has been shown to occur in advance of radiographic evidence of tumor progression. 9, 10 Outcome assessment in neuro-oncology is oriented predominantly toward radiographic changes and survival time. 11 Radiographic response, in particular, is not always the best indicator of patient status. For instance, with anti-angiogenic therapy, apparent radiographic response may reflect a normalization of tumor vasculature rather than a true antitumor effect. Patient-centered outcomes assessed with neurocognitive testing can provide supportive information about the clinical benefit achieved with increased response rates and survival and may help patients and physicians to make decisions about the potential benefits of treatment. Furthermore, antitumor therapies that have beneficial effects on NCF, in addition to being efficacious in terms of radiological response and survival, would be of value to patients with high-grade gliomas in terms of improved QoL and functional independence. 1 To date, there has been no evaluation of NCF in multisite clinical trials of patients with recurrent glioblastoma.
In the phase II BRAIN trial of patients with recurrent glioblastoma, 12 the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (BEV; Genentech), either alone or in combination with irinotecan (CPT-11), demonstrated improved objective response (OR) rates and 6-month progression-free survival (PFS) compared with historical controls. As an exploratory outcome in BRAIN, NCF was assessed with a battery of neurocognitive tests widely used in neuropsychological clinical practice and research studies in patients with brain tumors. 1, 9 We took advantage of the available data to describe NCF in a population of patients with recurrent glioblastoma, evaluate how NCF changed with treatment, and assess the overall feasibility of using neurocognitive testing to monitor NCF in this rapidly progressing disease.
Patients and Methods

Patients
One hundred sixty-seven patients with glioblastoma at first or second relapse were randomized to receive BEV (n ¼ 85) or BEV + CPT-11 (n ¼ 82) in the BRAIN study. BRAIN methodology, including study design, eligibility, treatment, assessments, and analyses, has been published in detail. 12 BRAIN is registered at www. clinicaltrials.gov (NCT00345163). The protocol was approved by the institutional review board at each study site, and all patients provided informed consent prior to participation in the study. All patients underwent clinical, laboratory, MRI, and neurocognitive testing at baseline and prior to the beginning of each treatment cycle (i.e., every 6 weeks) up to 52 weeks or until disease progression or discontinuation.
Neuroimaging
Co-primary endpoints of BRAIN, OR rate and 6-month PFS, were assessed by a blinded, independent radiology facility (IRF; RadPharm, Inc., Princeton, NJ) according to World Health Organization Response Evaluation Criteria, 13 taking corticosteroid dose into account.
14 Non-contrast-enhancing lesions were considered nontarget lesions in tumor assessment. Progression was determined by contrast-enhancing and non-contrastenhancing lesions. As mandated by the protocol, in the absence of radiographic documentation, clinical progression, assessed by the investigator according to his/ her judgment of neurological progression, was used to determine disease progression. (Notably, each determination of disease progression in BRAIN was based on radiographic documentation.) All patients were followed until discontinuation from the study, loss to follow-up, study termination, or death.
Neurocognitive Testing
Memory, visuomotor scanning speed, and executive function were evaluated using 3 objective, standard, valid tests ( Table 1 ). The maximum time to complete each test ranged from 3 to 5 min, for a total evaluation time of 25 min.
Statistical Analysis
For each NCF test, raw scores and standardized scores (mean ¼ 0, SD ¼ 1) using published normative data from a healthy population 15 -17 were calculated for analyses. For Trail Making Test Parts A and B, raw scores were prorated (percent prorated: Part A ¼ 4.73%, Part B ¼ 19.38%) if the test was discontinued or the maximal time was reached secondary to a neurological difficulty, according to the method described by Heaton et al. 16 If a test was not administered, or the patient was unable to attempt a test, it was excluded from the analysis. The percentage of patients with analyzable data (completed and/or prorated tests) for each NCF test at each assessment was calculated.
At each assessment, change in raw test score relative to baseline was calculated, and neurocognitive status was categorized as improved, stable, or declined, using the Reliable Change Index (RCI). 18 The RCI is derived from the standard error of measurement of each test and represents the 90% confidence interval for the difference in raw score from baseline to the next assessment that would be expected if no real change occurred:
where SEdiff is the standard error of difference, SEM is the standard error of measurement, SD is the standard deviation, and r xy is the test-retest reliability statistic. All RCI thresholds were rounded to the nearest whole number. Changes that did not meet the RCI threshold for improvement or decline were categorized as stable performance. Changes (i.e., improvement, decline) from baseline neurocognitive status were confirmed at the next neurocognitive assessment, when available. To assess the relationship among 3 clinical and radiographic tumor response outcomes and change in NCF, neurocognitive status relative to baseline was evaluated for 3 subgroups of patients at specific timepoints: patients with an IRF-determined OR at the time of first response, patients with IRF-determined PFS .6 months at the Week 24 assessment, and patients with investigator-determined progressive disease at the time of progression. Changes in standardized scores over time were also plotted for the first 2 subgroups of patients. Finally, concomitant medications that could affect NCF were summarized for patients who had an IRF-determined OR.
Results
Patient Demographics and Baseline Characteristics
Between June 2006 and February 2007, 167 patients with glioblastoma in first or second relapse were randomized to receive BEV (n ¼ 85) or BEV + CPT-11 (n ¼ 82) in the BRAIN study ( Table 2) . Negative mean standardized test scores in all tests indicated that patients were performing below the mean of the general population.
Neurocognitive Outcomes
Eighty-five to 98% of all patients completed the neurocognitive tests at baseline; and the majority of patients who remained on study completed tests at each assessment. Table 3 shows the percentage of patients who completed individual tests at baseline, Week 6, and Week 24). The majority of patients who had an IRF-determined OR or IRF-determined PFS .6 months had stable or (Table 4) . In contrast, the majority of the patients who had investigator-determined disease progression had declined on at least one test at the time of progression (BEV ¼ 69.4%; BEV + CPT-11 ¼ 56.0%; Table 4) , and .40% declined on multiple tests. Compared with the general population, patients with an IRF-determined OR or PFS .6 months had poorer performance on all neurocognitive tests at baseline ( Figs 1 and 2) ; and the median standardized scores of these patients remained stable from baseline to Week 24, with trends suggesting improvement in some patients.
Concomitant Medication
Given the low rate of use, it is unlikely that psychostimulants or opioids affected neurocognitive status at the time of IRF-determined OR. The prevalent use of anticonvulsants and corticosteroids makes it difficult to determine their effects, if any, on NCF in this patient population (Table 5 ).
Discussion
The BRAIN study evaluated NCF in the largest sample of patients with progressive glioblastoma to date. Test completion rates were high and consistent with other large multicenter trials, 19 indicating that the approximately 25-min assessment was feasible and not overly burdensome for patients with glioblastoma in first or second relapse or study sites.
Neurocognitive tests were sensitive to changes in NCF over time and demonstrated that, relative to baseline, the majority of patients who had an IRF-determined OR or PFS .6 months had improved or stable NCF at the time of response or at the 24-week assessment, respectively; while those who had investigator-determined progressive disease demonstrated evidence of neurocognitive decline at the time of progression.
Median test scores during the first 24 weeks on study for patients with an IRF-determined OR or PFS .6 months were generally stable, with trends suggesting improvement in some patients. While this is consistent with many anecdotal reports of significant improvement in patient NCF while on therapy, the absence of a control arm in the BRAIN study does not permit us to rule out the possibility that the trend suggesting improvement may also reflect practice effects, despite efforts to diminish this possibility by using alternate forms of the tests across time. 20 In some patients with recurrent glioblastoma, the degree of neurocognitive impairment can be so great at baseline that it is unlikely that subsequent test scores will exceed the RCI threshold necessary to determine a decline in NCF (i.e., floor effect). Sensitivity analyses in the subset of BEV-group patients who had an OR showed that only one of the neurocognitive tests, the HVLT-R-DR (Hopkins Verbal Learning Test-RevisedDelayed Recognition), showed a potential for floor effects. Even when taking this into account, the majority of responders did not experience a decline in NCF at the time of OR relative to baseline. Thus, although patients were quite cognitively debilitated at baseline relative to a healthy population, change from baseline NCF did not appear to have been influenced by potential floor effects.
Antiangiogenic therapies have complicated the interpretation of classic radiographic outcomes (e.g. van den Bent 2009; Wen et al. 2010), 21, 11 primarily due to the effects of tumor vasculature normalization confounding true antitumor effects. In the current trial there was evidence of a trend suggesting some degree of consistency between radiographically determined outcomes and NCF outcomes at key radiographic time points. However, in a substantial minority of patients there was discordance between radiographic outcomes and NCF outcomes. Further examination of these discrepancies in the future may enhance our understanding of the clinical impact of different radiographic features/ patterns.
In addition to alternative imaging modalities for tumor assessment and determination of response and progression, 11 data increasingly demonstrate that patient-centered endpoints, such as NCF, may be used to measure clinical benefit; 22 NCF is an attractive endpoint, as it provides a direct, objective, valid, and standardized measure of a cardinal, early, and frequent symptom of brain tumor. 22, 23 In high-grade glioma, pretreatment NCF 24 and NCF 16 months after treatment 25 were predictive of survival, even after controlling for age, KPS, histology, and time since diagnosis. 1 Changes in NCF can occur in a predictable relationship with evidence of changing lesion burden, as seen in the current analysis; and they have also been demonstrated to occur in advance of radiographic evidence of tumor progression. 7, 9, 10 Additionally, NCF is a direct measure of patient well-being that is associated with functional independence, and subjective QoL 2,5,6 is more sensitive to disease progression than self-reported QoL, 2, 5, 6 activities of daily living, 1, 5, 6 and the results of mental status screening tests, such as the Mini-Mental State Examination. 26, 27 Furthermore, decline in NCF is associated with caregiver distress and burden. 4, 5 As demonstrated in this analysis of BRAIN participants, integrating NCF testing as an outcome in brain tumor trials is feasible and yields critical information about clinical benefit that may not be captured by radiographic imaging alone. Of note, potential confounding variables, such as treatment toxicities or unrecognized comorbidities (e.g., subclinical seizures) were not taken into account when assessing NCF.
To summarize, NCF testing with objective and valid tests to measure patient functioning was feasible in patients with recurrent glioblastoma. The majority of patients who had an IRF-determined OR or PFS .6 months had improved or stable NCF at the time of response or at the 24-week assessment, respectively; and most patients who had investigator-determined progressive disease demonstrated evidence of neurocognitive decline at the time of progression. Inclusion of a control or comparison arm in future studies will facilitate more detailed interpretations of these data. 
